PTGX - プロタゴニスト・セラピュ―ティクス (Protagonist Therapeutics Inc.)

PTGXのニュース

   Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update  2022/02/28 21:05:00 PR Newswire
NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "This past quarter and the year leading up…
   Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month.  2022/02/26 15:00:00 Marketing Sentinel
In last trading session, Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw 0.54 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $24.49 trading at $0.24 or 0.99% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of PTGX’s stock is … Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. Read More »
   Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference  2022/02/10 12:00:00 Kwhen Finance
   Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds  2022/01/12 16:26:26 Insider Monkey
In this article we will check out the progression of hedge fund sentiment towards Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and determine whether it is a good investment right now.
   Protagonist Therapeutics (NASDAQ:PTGX) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Financial Survey  2021/12/22 08:14:42 Dakota Financial News
Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []
   Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is BVF Inc. ILs 4th Largest Position  2021/11/01 15:14:43 Dakota Financial News
BVF Inc. IL cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 5.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,754,095 shares of the companys stock after selling 205,356 shares during the period. Protagonist Therapeutics comprises approximately 6.3% of []
   There Is A Lot Of Upside Potential For Protagonist Therapeutics Inc.(NASDAQ: PTGX)  2021/10/30 18:00:00 Stocks Register
Protagonist Therapeutics Inc. (NASDAQ:PTGX) price on Friday, October 29, fall -3.74% below its previous days close as a downside momentum from buyers pushed the stocks value to $31.16. A look at the stocks price movement, the close in the last trading session was $32.37, moving within a range at $30.84 and $32.42. The beta value There Is A Lot Of Upside Potential For Protagonist Therapeutics Inc.(NASDAQ: PTGX) Read More »
   -$0.67 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter  2021/10/29 19:38:43 Dakota Financial News
Brokerages predict that Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will post earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Protagonist Therapeutics earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.77). Protagonist Therapeutics posted earnings per share []
   Commodore Capital LP Decreases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)  2021/10/27 15:04:41 Dakota Financial News
Commodore Capital LP lowered its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 39.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 210,600 shares of the companys stock after selling 139,000 shares during the period. Protagonist Therapeutics makes up approximately 3.3% of Commodore Capital LPs portfolio, making the stock its 14th biggest holding. []
   Dimensional Fund Advisors LP Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)  2021/10/23 08:48:45 Dakota Financial News
Dimensional Fund Advisors LP boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 20.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 791,016 shares of the companys stock after purchasing an additional 134,915 shares during the quarter. Dimensional Fund Advisors []
   Iszo Capital Management Lp Buys Anterix Inc, Protagonist Therapeutics Inc, Chico''s FAS Inc, ...  2021/08/24 01:38:23 GuruFocus
Related Stocks: ATEX , PTGX , CHS ,
   Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma  2021/08/10 12:05:00 Benzinga
NEWARK, Calif. , Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future development and sales milestone payments and royalties owed to Zealand for Protagonist''s product candidate rusfertide under the companies'' 2012 Collaboration Agreement. Under the terms of an agreement that ends arbitration proceedings Protagonist initiated in 2020, future development and sales milestone payments (other than $2.5 million in near-term milestones) and royalties for rusfertide have been reduced by 50%. Milestones and royalty payments will be due for sales and milestones achieved by either Protagonist or any future rusfertide licensee or partner. Protagonist will also make a $1.5 million payment to Zealand in Full story available on Benzinga.com
   Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress  2021/08/04 20:05:00 PR Newswire
NEWARK, Calif., Aug. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the second quarter ended June 30, 2021, and an overview of recent company progress. "The second quarter of 2021 was one of
   Leerink Partners Stick to Their Buy Rating for Protagonist Therapeutics By Investing.com  2021/08/01 06:59:11 Investing.com
Leerink Partners Stick to Their Buy Rating for Protagonist Therapeutics
   The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres'' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO  2021/07/22 12:18:01 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced new preclinical data for its lead drug candidate atuzaginstat in periodontal disease) Intuitive Surgical, Inc. (NASDAQ: ISRG ) (reacted to better-than-expected second-quarter results) Forward Pharma A/S (NASDAQ: FWP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 21) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Cyteir Therapeutics, Inc. (NASDAQ: CYT ) Elevation Oncology, Inc. (NASDAQ: ELEV ) Ensysce Biosciences, Inc. (NASDAQ: ENSC ) ERYTECH Pharma S.A. (NASDAQ: ERYP ) HCW Biologics Inc. (NASDAQ: HCWB ) (IPOed Tuesday) Lumos Pharma, Inc. (NASDAQ: LUMO ) ( signaled a delay in clinical trials of its treatment for pediatric growth deficiency) Medicenna Therapeutics Corp. (NASDAQ: MDNA ) Nautilus Biotechnology, Inc. (NASDAQ: NAUT ) OptiNose, Inc. (NASDAQ: OPTN ) POINT Biopharma Global Inc. (NASDAQ: PNT ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) (IPOed Friday) VectivBio Holding AG (NASDAQ: VECT ) Yumanity Therapeutics, Inc. (NASDAQ: YMTX ) Stocks In Focus Erytech Plans Regulatory Submission For Eryaspase In Blood Cancer Following Positive Pre-BLA Meeting Erytech said it intends to move forward toward the submission of a biologic license application to the U.S.

calendar